JP2012523430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012523430A5 JP2012523430A5 JP2012504880A JP2012504880A JP2012523430A5 JP 2012523430 A5 JP2012523430 A5 JP 2012523430A5 JP 2012504880 A JP2012504880 A JP 2012504880A JP 2012504880 A JP2012504880 A JP 2012504880A JP 2012523430 A5 JP2012523430 A5 JP 2012523430A5
- Authority
- JP
- Japan
- Prior art keywords
- degenerative disorder
- piperzine
- diol
- prodrug
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000003412 degenerative effect Effects 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 claims 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102000019355 Synuclein Human genes 0.000 claims 1
- 108050006783 Synuclein Proteins 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 102000003802 alpha-Synuclein Human genes 0.000 claims 1
- 108090000185 alpha-Synuclein Proteins 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 150000002339 glycosphingolipids Chemical class 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16810109P | 2009-04-09 | 2009-04-09 | |
| US61/168,101 | 2009-04-09 | ||
| PCT/US2010/030470 WO2010118282A1 (en) | 2009-04-09 | 2010-04-09 | Methods for preventing and/or treating degenerative disorders of the central nervous system |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012523430A JP2012523430A (ja) | 2012-10-04 |
| JP2012523430A5 true JP2012523430A5 (enExample) | 2013-05-16 |
| JP5634498B2 JP5634498B2 (ja) | 2014-12-03 |
Family
ID=42934882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012504880A Active JP5634498B2 (ja) | 2009-04-09 | 2010-04-09 | 中枢神経系の変性障害の予防および／または治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8304429B2 (enExample) |
| EP (1) | EP2416655B1 (enExample) |
| JP (1) | JP5634498B2 (enExample) |
| CN (1) | CN102448306B (enExample) |
| AU (1) | AU2010233187B2 (enExample) |
| BR (1) | BRPI1015472A2 (enExample) |
| CA (1) | CA2758187C (enExample) |
| ES (1) | ES2505243T3 (enExample) |
| IL (1) | IL215584A (enExample) |
| NZ (1) | NZ595630A (enExample) |
| WO (1) | WO2010118282A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2758271C (en) * | 2009-04-09 | 2018-06-05 | Robert Boyd | Methods for preventing and/or treating lysosomal storage disorders |
| CN102647905B (zh) | 2009-10-19 | 2015-09-09 | 阿米库斯治疗学公司 | 用于预防和/或治疗溶酶体贮积失调的新颖组合物 |
| KR101880411B1 (ko) | 2009-10-19 | 2018-07-19 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물 |
| EP2640853B1 (en) | 2010-11-17 | 2018-12-26 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| WO2013070981A2 (en) * | 2011-11-08 | 2013-05-16 | University Of Central Florida Research Foundation, Inc. | Treating er stress related disorders by stabilizing intracellular calcium homeostasis |
| US9155695B2 (en) | 2013-03-14 | 2015-10-13 | Medtronic, Inc. | Injectable ropinirole compositions and methods for making and using same |
| EP3087056A4 (en) | 2013-12-23 | 2017-07-19 | Alectos Therapeutics Inc. | Glucocerebrosidase modulators and uses thereof |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| US10300155B2 (en) | 2015-12-31 | 2019-05-28 | Washington University | Alpha-synuclein ligands |
| CA3036511A1 (en) * | 2016-09-12 | 2018-03-15 | Steven Hoffman | Compositions for treating dementia |
| RU2019114679A (ru) * | 2016-11-15 | 2020-12-17 | Х. Лундбекк А/С | Средства, пути применения и способы лечения синуклеопатии |
| BR112020013994A2 (pt) | 2018-01-12 | 2020-12-08 | Bristol-Myers Squibb Company | Oligonucleotídeos antissenso que direcionam alfa-sinucleína e seus usos |
| KR102839166B1 (ko) | 2018-01-12 | 2025-07-28 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시누클레인을 표적화하는 안티센스 올리고뉴클레오티드 및 그의 용도 |
| CN119606967B (zh) * | 2024-12-13 | 2025-09-05 | 合肥工业大学 | 氯雷他定在制备用于预防和治疗血管钙化药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE243196T1 (de) * | 1994-03-09 | 2003-07-15 | Novo Nordisk As | Piperidine und pyrrolidine |
| AU2002306848A1 (en) * | 2001-03-23 | 2002-10-08 | Elan Pharmaceuticals, Inc. | Methods of treating alzheimer's disease with piperidin derivates |
| US6770625B2 (en) * | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| US6670625B1 (en) * | 2002-06-18 | 2003-12-30 | Ge Medical Systems Global Technology Company, Llc | Method and apparatus for correcting multipole aberrations of an electron beam in an EBT scanner |
| EP1558245A2 (en) * | 2002-10-28 | 2005-08-03 | Novo Nordisk A/S | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
| MX2007015602A (es) * | 2005-06-08 | 2008-02-21 | Amicus Therapeutics Inc | Tratamiento de trastornos del sistema nervioso central asociados con mutaciones en genes que codifican las enzimas lisosomicas. |
| JP5303458B2 (ja) * | 2006-06-23 | 2013-10-02 | アミークス セラピューティックス インコーポレイテッド | β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法 |
| US20080009156A1 (en) | 2006-07-10 | 2008-01-10 | Malin Glen K | System and method for bonding coaxial cable |
| CA2758271C (en) * | 2009-04-09 | 2018-06-05 | Robert Boyd | Methods for preventing and/or treating lysosomal storage disorders |
-
2010
- 2010-04-09 JP JP2012504880A patent/JP5634498B2/ja active Active
- 2010-04-09 BR BRPI1015472A patent/BRPI1015472A2/pt not_active Application Discontinuation
- 2010-04-09 EP EP10762468.6A patent/EP2416655B1/en active Active
- 2010-04-09 AU AU2010233187A patent/AU2010233187B2/en not_active Ceased
- 2010-04-09 CN CN201080024142.1A patent/CN102448306B/zh not_active Expired - Fee Related
- 2010-04-09 WO PCT/US2010/030470 patent/WO2010118282A1/en not_active Ceased
- 2010-04-09 US US12/757,144 patent/US8304429B2/en not_active Expired - Fee Related
- 2010-04-09 NZ NZ595630A patent/NZ595630A/xx not_active IP Right Cessation
- 2010-04-09 ES ES10762468.6T patent/ES2505243T3/es active Active
- 2010-04-09 CA CA2758187A patent/CA2758187C/en not_active Expired - Fee Related
-
2011
- 2011-10-06 IL IL215584A patent/IL215584A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012523430A5 (enExample) | ||
| JP2012523431A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2010510202A5 (enExample) | ||
| JP2016513734A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| FI2291080T5 (fi) | Uusia sfingosiinifosfaattireseptorimodulaattoreita | |
| HRP20151443T1 (hr) | Terapijsko sredstvo protiv stenoze kralježniäśnog kanala | |
| MX2010005342A (es) | Compuestos indola y metodos para tratar el dolor visceral. | |
| RU2018103338A (ru) | Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием | |
| JP2015523407A5 (enExample) | ||
| JP2015500257A5 (enExample) | ||
| WO2008119057A3 (en) | The use of pde7 inhibitors for the treatment of movement disorders | |
| MX354423B (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
| NZ595630A (en) | Methods for preventing and/or treating degenerative disorders of the central nervous system | |
| JP2010518061A5 (enExample) | ||
| CL2010000059A1 (es) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)-3,5-diflurobenzamida o una sal farmaceuticamente aceptable; forma polimorfica de la sal clorhidrato; composicion farmaceutica; y su uso para tratar una enfermedad del sistema nervioso central tal como dolor, sindrome metabolico, inflamacion, alzheimer. | |
| NZ595629A (en) | Methods for preventing and/or treating lysosomal storage disorders | |
| HRP20121078T1 (hr) | Farmaceutski sastav za lijeäśenje hiperaktivnog mjehura | |
| JP2013516488A (ja) | 炭酸脱水酵素阻害薬およびさらなる活性剤の組み合わせによる閉塞型睡眠時無呼吸症候群の治療 | |
| JP2018537513A5 (enExample) | ||
| JP2016512817A5 (enExample) | ||
| JP2015520221A5 (enExample) | ||
| EA201270602A1 (ru) | N-((1r,2s,5r)-5-(трет-бутиламино)-2-((s)-3-(7-трет-бутилпиразоло[1,5-а][1,3,5]триазин-4-иламино)-2-оксопирролидин-1-ил)циклогексил)ацетамид в качестве двойного модулятора активности хемокиновых рецепторов, его кристаллические формы и способы получения | |
| JP2014532643A5 (enExample) |